关键词：帕金森氏症；神经变性疾病；多巴胺
摘 要：The Global Parkinson's Disease market is expected to grow at a steady pace during the period 2012-2016. The market was dominated by the Americas in 2012, and was followed by the EMEA and APAC regions. Currently, a major part of the market growth is derived from the Dopamine Agonists segment. Other segments, such as the COMT Inhibitor segment and the Dopamine Replacement Agents segment, are expected to make significant contributions to the revenue of the overall market in the next few years. Factors such as the lack of efficacious products in the market, various patent expirations, and a weak pipeline are expected to limit the growth of the Global Parkinson's Disease market during the forecast period. Currently, the market has limited treatment options and numerous unmet needs in Parkinson's disease treatment. However, new entrants are expected to gain a significant market share during the forecast period as they are developing numerous novel molecules which have the potential to alter the progression of the disease. The Global Parkinson's Disease market is expected to post a CAGR of 1.67 percent during the forecast period.
目 录：01. Executive Summary

02. List of Abbreviations

03. Introduction

04. Market Research Methodology

Market Research Process

Research Design

Research Methodology

05. Scope of the Report

Market Overview

Product Offerings

06. Market Landscape

06.1 Global Parkinson's Disease Market

Market Size and Forecast

06.2 Market Segmentation by Drug Class

06.3 Five Forces Analysis

07. Geographical Segmentation

08. Key Leading Countries

USA

Germany

Japan

09. Rate of Incidence and Prevalence

10. Vendor Landscape

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Key Vendor Analysis

17.1 GlaxoSmithKline plc

Business Overview

Key Information

SWOT Analysis

17.2 Novartis AG

Business Overview

Key Information

SWOT Analysis

17.3 Orion Corp.

Business Overview

Key Information

SWOT Analysis

17.4 Teva Pharmaceuticals Industries Ltd.

Business Overview

Key Information

SWOT Analysis

18. Other Reports in this Series